Human Papillomavirus-Related Carcinoma
Conditions
Keywords
tailored intervention, college aged students, HPV
Brief summary
This study will test whether a tailored, online educational intervention increases HPV vaccine uptake and intent among female college students.
Detailed description
MeFirst is the first web-based, online, educational tool designed to promote Human Papillomavirus (HPV) vaccine awareness and understanding in an effort to improve HPV vaccine intent and uptake among female university students. HPV is the most common sexually transmitted infection and causes genital warts and cancer. The HPV vaccine has been recommended for girls ages 11-26 since 2006, yet vaccination rates remain low. Tailored online interventions may be more effective tools to promote behavior change among college students than traditional static interventions. The proposed study is a randomized controlled trial testing the efficacy of the MeFirst tool vs. standard static educational material on increasing HPV vaccination intent and uptake among female university students aged 18-26.
Interventions
BEHAVIORALMeFirst Tailored Intervention
Participants will be lead through MeFirst, an interactive web-based tool that is tailored to their responses during the survey. This tool provides information regarding HPV Vaccination.
Sponsors
University of Michigan
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 26 Years
Healthy volunteers
Yes
Inclusion criteria
* enrolled at the University of Michigan
Exclusion criteria
* receipt of any doses of HPV vaccine
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Determine the effect of the MeFirst tool, a tailored, online HPV vaccination decision-making guide, on HPV vaccination intention and/or uptake. | Immediately post intervention, 3 months and 12 months | Intention will be assessed on a five-point scale immediately after and at 3 and 12 months. Uptake will be assessed by yes/no/don't know response to the statement, I have received at least 1 dose of the HPV vaccine at 3 and 12 months. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Determine the effect of the MeFirst tool on HPV-related knowledge. | Immediately post intervention, 3 months and 12 months | Comparing 5 or 10-point scales measuring participants' HPV-related knowledge (HPV, HPV vaccination, and cervical cancer) immediately post-intervention and at 3 months and 12 months. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Determine acceptability of the MeFirst tool to participants. | Immediately post intervention, 3 months and 12 months | Participants answer five 5-point scale questions about the acceptability of the MeFirst tool immediately post intervention, and at 3 months and 12 months. |
Countries
United States
Outcome results
None listed